Removing endotoxin from biopharmaceutical solutions - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Removing endotoxin from biopharmaceutical solutions


Pharmaceutical Technology Europe
Volume 21, Issue 10

Recombinant biopharmaceuticals are manufactured using complex biological systems, such as bacteria, yeast, baculoviruses or mammalian cells. However, regulating consistent yields, monitoring contamination and validating product efficacy during the manufacturing process are areas of concern and represent major challenges for biopharmaceutical manufacturers.


flashfilm/Getty Images
High batch rejection rates of biopharmaceuticals, which are common during production, can usually be attributed to contamination by biological agents such as microorganisms or byproducts produced by these microorganisms, including toxins or pyrogens. Endotoxin contamination of biopharmaceuticals is a serious issue and may infringe on workforce safety. Apart from adherence to FDA regulations and strict international quality standards, many US pharmaceutical companies must also deal with the Occupational Health and Safety Administration, which ensures that contamination control is much more than just a housekeeping activity. In Europe, this task is taken up by the European Agency for Safety and Health at Work.

Bacterial endotoxin is another term used for lipopolysaccharides (LPS), complexes that are located in the outer cell membrane of Gram-negative bacteria and blue-green algae.1 Gram-negative bacteria are widely used in biopharm manufacturing to produce recombinant DNA products, such as therapeutic proteins. LPS subunits are complex amphiphilic molecules with a molecular weight (MW) of approximately 10–20 kDa2,3 and vary widely in chemical composition both between and among bacterial species. LPS complexes tend to aggregate and form large structures that have an average MW > 10 kDa.

LPS is a potential cause of pyrogenic reactions in parenteral drug products because these complexes can act as a strong immunostimulant that activates the complement system by the alternative (properdin) pathway4 upon entry into the human blood circulation. This can cause death of the individual who is administered with the drug.5,6

A pyrogenic reaction can be caused by only a small amount of endotoxin — approximately 0.1 ng/kg of body weight. The standard reporting unit for endotoxin data is one endotoxin unit (EU) — the equivalent of 0.1 ng. A typical gram-negative bacterium contains 10–15 g of LPS, which means that at least 105 bacterial cells are required to contribute 0.1 ng of endotoxin.

The chemical structure of endotoxin


Figure 1: Lipopolysaccharide (LPS) structure and location in the bacterial membrane.
LPS consists of three components or regions: Lipid A, an R-polysaccharide and an O-polysaccharide (Figure 1).

Somatic (O) antigen or O-polysaccharide is attached to the core polysaccharide and consists of repeating oligosaccharide subunits made up of three to five sugars. The O-polysaccharide maintains the hydrophilic domain of the LPS molecule and also contains the major antigenic determinant (antibody-combining site) of the gram-negative cell wall.

Toxicity of endotoxin has been found to be associated with Lipid A, whilst immunogenicity is associated with the polysaccharide components.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology Europe,
Click here